Intellia Therapeutics, Inc. (NTLA) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-08-04. Read in-app with summaries. First-party data.
Corporate Presentation: Intellia Therapeutics is advancing in vivo CRISPR-based therapies, targeting a U.S. commercial launch for lonvoguran ziclumeran (lonvo-z) in HAE in early 2027.
NTLA overview · NTLA earnings · NTLA financials · NTLA KPIs · NTLA documents · NTLA ownership · NTLA peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.